Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials
Francis Berenbaum*, Thomas Schnitzer, Alan Kivitz, Lars Viktrup, Elizabeth Johnston, Ruoyong Yang, Ed Whalen, Leslie Tive, David Semel
Dive into the research topics of 'Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials'. Together they form a unique fingerprint.